| Primary information |
|---|
| sequence ID | Seq_3747 |
| Peptide sequence | IHWESASLL |
| CancerPDF_ID | CancerPDF_ID24, CancerPDF_ID939, CancerPDF_ID1040, CancerPDF_ID1460, CancerPDF_ID2661, CancerPDF_ID8551, CancerPDF_ID9597, CancerPDF_ID12696, |
| PMID | 16896061,19795908,16395409,21136997,21136997,23667664,21533267,27058005 |
| Protein Name | Complement C3f,Complement C3,Complement C3f,Complement C3,Complement C3,Complement C3f,Complement C3,Complement C3 |
| UniprotKB Entry Name | CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum,Plasma,Serum,Serum,Serum |
| M/Z | 1055.6,528.27,1055.6,1054.54475,1054.5448,1054.54,528.26,1055.082 |
| Charge | 1,2,1,1,1,1,2,NA |
| Mass (in Da) | 1055.55,NA,NA,NA,NA,1056.21,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,LC-MS,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,LC-MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,NA,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,NA,NA,NA,1.49,NA |
| CancerPDF_ID | CancerPDF_ID24, CancerPDF_ID939, CancerPDF_ID1040, CancerPDF_ID1460, CancerPDF_ID2661, CancerPDF_ID8551, CancerPDF_ID9597, CancerPDF_ID12696, |
| p-Value | 1.00E-05,NA,1.22E-13,NA,NA,NA,NA,"less than 0.05,0.012,0.274" |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT,Proteome Discoverer |
| Length | 9,9,9,9,9,9,9,9 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Breast cancer |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,NA,Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,27 healthy individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)." |
| Regulation | NA,NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 227, 1051 and 1 in prostate, bladder and breast cancer respectively",NA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Upregulated with the fold change of 1.21 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.27, Upregulated in BC vs healthy with 1.126 fold change" |
| Validation | Independent validation,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,NA,MRM-based validation of 19 candidates,NA |
| Sensitivity | 95% on independent dataset,NA,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,NA,NA,NA,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,97.5 % on validation dataset,NA,NA,NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | 533899
|